Trends in buprenorphine treatment disparities during the COVID pandemic in Massachusetts

References

• Ahmad FB, Rossen LM, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics; 2021. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm. Accessed November 23, 2021.
   Google Scholar
• Larochelle MR, Slavova S, Root ED, et al. Disparities in opioid overdose death trends by race/ethnicity, 2018–2019, from the HEALing Communities Study. Am J Public Health. 2021;111(10):1851–1854.
   PubMed Web of Science ®Google Scholar
• Massachusetts Department of Public Health. Opioid-related overdose deaths, all intents, MA residents – demographic data highlights. https://www.mass.gov/doc/opioid-related-overdose-deaths-demographics-november-2021/download Accessed November 23, 2021.
   Google Scholar
• Khatri UG, Pizzicato LN, Viner K, et al. Racial/ethnic disparities in unintentional fatal and nonfatal emergency medical services–attended opioid overdoses during the COVID-19 pandemic in Philadelphia. JAMA Netw Open. 2021;4(1):e2034878.
   PubMed Web of Science ®Google Scholar
• Banks DE, Carpenter RW, Wood CA, Winograd RP. Commentary on Furr-Holden et al.: as opioid overdose deaths accelerate among Black Americans, COVID-19 widens inequities-a critical need to invest in community-based approaches. Addiction. 2021;116(3):686–687.
   PubMedGoogle Scholar
• Hatcher AE, Mendoza S, Hansen H. At the expense of a life: race, class, and the meaning of buprenorphine in pharmaceuticalized “care”. Subst Use Misuse. 2018;53(2):301–310.
   PubMed Web of Science ®Google Scholar
• Lagisetty PA, Ross R, Bohnert A, Clay M, Maust DT. Buprenorphine treatment divide by race/ethnicity and payment. JAMA Psychiatry. 2019;76(9):979–981.
   PubMed Web of Science ®Google Scholar
• Hansen HB, Siegel CE, Case BG, Bertollo DN, DiRocco D, Galanter M. Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City. J Behav Health Serv Res. 2013;40(3):367–377.
   PubMed Web of Science ®Google Scholar
• Schuler MS, Dick AW, Stein BD. Growing racial/ethnic disparities in buprenorphine distribution in the United States, 2007–2017. Drug Alcohol Depend. 2021;223:108710.
   PubMedGoogle Scholar
• Lapham G, Boudreau DM, Johnson EA, et al. Prevalence and treatment of opioid use disorders among primary care patients in six health systems. Drug Alcohol Depend. 2020;207:107732.
   PubMed Web of Science ®Google Scholar
• Hadland SE, Wharam JF, Schuster MA, Zhang F, Samet JH, Larochelle MR. Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001–2014. JAMA Pediatr. 2017;171(8):747–755.
   PubMed Web of Science ®Google Scholar
• Samuels EA, Clark SA, Wunsch C, et al. Innovation during COVID-19: improving addiction treatment access. J Addict Med. 2020;14(4):e8–e9.
   PubMed Web of Science ®Google Scholar
• Zeileis A, Lumley T, Graham N, Koell S. Sandwich: robust covariance matrix estimators. R package version 3.0-1; 2021. https://cran.r-project.org/package=sandwich
   Google Scholar
• Fox J, Weisberg S. An R Companion to Applied Regression. 3rd ed. California: Sage Publications; 2019.
   Google Scholar
• Cantor J, Dick AW, Haffajee R, et al. Use of buprenorphine for those with employer-sponsored insurance during the initial phase of the COVID-19 pandemic. J Subst Abuse Treat. 2021;129:108384.
   PubMedGoogle Scholar
• Melin K, Santiago Quiñones D, Rodríguez-Díaz CE. Socially distant and out of reach: unintended consequences of COVID-19 prevention efforts on transgender and gender non-binary populations in Puerto Rico. J Subst Abuse Treat. 2021;122:108209.
   PubMed Web of Science ®Google Scholar
• Andraka-Christou B. Addressing racial and ethnic disparities in the use of medications for opioid use disorder. Health Aff. 2021;40(6):920–927.
   PubMed Web of Science ®Google Scholar
• Nguemeni Tiako MJ. Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid COVID-19. J Subst Abuse Treat. 2021;122:108214.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. The opioid crisis and the Black/African American population: an urgent issue. Publication No. PEP20-05-02-001. Office of Behavioral Health Equity. Substance Abuse and Mental Health Services Administration; 2020.
   Google Scholar
• Kariisa M, Seth P, Scholl L, Wilson N, Davis NL. Drug overdose deaths involving cocaine and psychostimulants with abuse potential among racial and ethnic groups – United States, 2004–2019. Drug Alcohol Depend. 2021;227:109001.
   PubMed Web of Science ®Google Scholar
• Society for Adolescent Health and Medicine. Medication for adolescents and young adults with opioid use disorder. J Adolesc Health 2021;68(3):632–636.
   PubMedGoogle Scholar
• Kilaru AS, Xiong A, Lowenstein M, et al. Incidence of treatment for opioid use disorder following nonfatal overdose in commercially insured patients. JAMA Netw Open. 2020;3(5):e205852.
   PubMed Web of Science ®Google Scholar
• Choi S, Stein MD, Raifman J, Rosenbloom D, Clark JA. Estimating the impact on initiating medications for opioid use disorder of state policies expanding Medicaid and prohibiting substance use during pregnancy. Drug Alcohol Depend. 2021;229(Pt A):109162.
   PubMedGoogle Scholar
• Guerrero E, Amaro H, Kong Y, Khachikian T, Marsh JC. Gender disparities in opioid treatment progress in methadone versus counseling. Subst Abuse Treat Prev Policy. 2021;16(1):52.
   PubMed Web of Science ®Google Scholar
• Carroll JJ, El-Sabawi T, Ostrach B. The harms of punishing substance use during pregnancy. Int J Drug Policy. 2021;98:103433.
   PubMedGoogle Scholar
• Haffajee RL, Faherty LJ, Zivin K. Pregnant women with substance use disorders – the harm associated with punitive approaches. N Engl J Med. 2021;384(25):2364–2367.
   PubMedGoogle Scholar
• Samples H, Williams AR, Olfson M, Crystal S. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. J Subst Abuse Treat. 2018;95:9–17.
   PubMed Web of Science ®Google Scholar